VIVET THERAPEUTICS
Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
VIVET THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care
Founded:
2016-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.vivet-therapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+33684755087
Email Addresses:
[email protected]
Total Funding:
87.4 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress Font Awesome Mobile Non Scaleable Content HSTS IPv6
Similar Organizations
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Dianthus Therapeutics
Dianthus Therapeutics is a biotech company developer of therapeutics and drugs.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Matterhorn Biosciences
Matterhorn Biosciences is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule.
Resolution Therapeutics
Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.
ZOE Health Study
ZOE Health Study is a biotechnology research company that offers technology to unlock the secrets of the immune system.
Current Employees Featured
Founder
Investors List
France 2030
France 2030 investment in Grant - Vivet Therapeutics
Pfizer
Pfizer investment in Corporate Round - Vivet Therapeutics
HealthCap
HealthCap investment in Series A - Vivet Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series A - Vivet Therapeutics
Kurma Partners
Kurma Partners investment in Series A - Vivet Therapeutics
Columbus Venture Partners
Columbus Venture Partners investment in Series A - Vivet Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Vivet Therapeutics
Ysios Capital
Ysios Capital investment in Series A - Vivet Therapeutics
Eurazeo
Eurazeo investment in Seed Round - Vivet Therapeutics
Official Site Inspections
http://www.vivet-therapeutics.com Semrush global rank: 13.84 M Semrush visits lastest month: 68
- Host name: manager-8412.wistee.fr
- IP address: 94.124.84.12
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Vivet Therapeutics"
Accueil - Vivet Therapeutics
Vivet is a strong team of experienced scientists and technical experts who are passionate about innovative science and dedicated to improving patients’ lives by curing genetic disorders. We …See details»
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing …
Sep 23, 2020 · Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) technologies developed through its partnerships with, and exclusive …See details»
About us - Vivet Therapeutics
VTX-801 – Wilson’s disease > VTX-801 in Wilson disease – GATEWAY; VTX-802 & VTX-803 – PFIC; VTX-804 – Citrullinemia Type 1; VTX – 806 – Cerebrotendinous XanthomatosisSee details»
Vivet Therapeutics - Crunchbase Company Profile
Vivet Therapeutics is a biotechnology company developing gene therapy treatments for orphan diseases. Vivet Therapeutics received EUR 4.9 million in financing. View contacts for Vivet Therapeutics to access new leads and …See details»
Vivet Therapeutics - Navarra Health Cluster
Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.See details»
Vivet Therapeutics - LinkedIn
Vivet Therapeutics | 5,117 followers on LinkedIn. Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.See details»
Our DNA - Vivet Therapeutics
Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.See details»
VTX-801 Receives U.S. FDA Fast Track Designation for …
Aug 12, 2021 · VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease. …See details»
Vivet Therapeutics - Leadership Team - The Org
The Leadership Team at Vivet Therapeutics drives the strategic vision and operational execution of the company's gene therapy programs for orphan diseases. Comprised of industry experts …See details»
Pfizer Secures Exclusive Option to Acquire Gene Therapy Company …
PARIS & Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, …See details»
Vivet Therapeutics’ Wilson Disease Gene Therapy Clinical Trial …
Sep 20, 2023 · Vivet Therapeutics is sponsoring the GATEWAY clinical trial. Vivet is dedicated to the development of innovative therapies for people affected by rare liver disorders such as …See details»
Pfizer buys into Vivet | C&EN Global Enterprise - ACS Publications
Mar 25, 2019 · Adding to the flurry of gene-therapy deals, Pfizer has paid roughly $51 million for a 15% stake in Vivet Therapeutics, which is developing liver-directed gene therapies.See details»
Vivet Therapeutics. Entrepreneurship. Cima Universidad de Navarra.
Vivet Therapeutics (Vivet) is a biotechnology company partnering with FIMA at Cima Universidad de Navarra. Vivet was founded by well-known international investors for the development of …See details»
Vivet Therapeutics and Pfizer Inc. Announce FDA - GlobeNewswire
Nov 18, 2020 · PARIS, France and NEW YORK, N.Y.—November 18, 2020— Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments …See details»
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 …
PARIS, April 8, 2024 /PRNewswire/ -- Vivet Therapeutics ('Vivet'), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic...See details»
Vivet Therapeutics Presents Interim Data from its Phase 1/2 …
Jun 5, 2024 · Vivet Therapeutics ("Vivet"), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the …See details»
Our leadership - Vivet Therapeutics
VTX-801 – Wilson’s disease > VTX-801 in Wilson disease – GATEWAY; VTX-802 & VTX-803 – PFIC; VTX-804 – Citrullinemia Type 1; VTX – 806 – Cerebrotendinous XanthomatosisSee details»
VTX-801 Receives U.S. FDA Fast Track Designation for the
Aug 12, 2021 · VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single …See details»
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to ...
Nov 18, 2020 · PARIS, France and NEW YORK, N.Y.—November 18, 2020— Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments …See details»
Vivet Therapeutics Raises €37.5 Million in Series A Financing …
May 4, 2017 · Vivet Therapeutics ('Vivet'), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in …See details»